Incyte Corporation (INCY)
| Market Cap | 23.59B +80.8% |
| Revenue (ttm) | 5.36B +21.5% |
| Net Income | 1.43B +6,631.4% |
| EPS | 7.06 +7,175.4% |
| Shares Out | 199.78M |
| PE Ratio | 16.53 |
| Forward PE | 41.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 478,530 |
| Open | 117.71 |
| Previous Close | 116.69 |
| Day's Range | 116.70 - 119.13 |
| 52-Week Range | 69.70 - 119.60 |
| Beta | 0.76 |
| Analysts | Buy |
| Price Target | 114.55 (-2.97%) |
| Earnings Date | Jul 28, 2026 |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo... [Read more]
Financial Performance
In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.
Financial StatementsAnalyst Summary
According to 26 analysts, the average rating for INCY stock is "Buy." The 12-month stock price target is $114.55, which is a decrease of -2.97% from the latest price.
News
Incyte price target raised to $110 from $105 at JPMorgan
JPMorgan raised the firm’s price target on Incyte (INCY) to $110 from $105 and keeps a Neutral rating on the shares.
Incyte price target raised to $104 from $103 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Incyte (INCY) to $104 from $103 and keeps an Equal Weight rating on the shares. Q2 earnings should reinforce a shift from…
Halozyme announces global collaboration, license agreement with Incyte
Halozyme Therapeutics (HALO) announced that it has entered into a global collaboration and license agreement with Incyte (INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-...
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets SAN DIEGO, July 20, 2026 /PRNewsw...
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Data to Be Highlighted in Four Rapid Oral Presentations at ESMO 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers.
Incyte price target raised to $136 from $124 at BofA
BofA raised the firm’s price target on Incyte (INCY) to $136 from $124 and keeps a Buy rating on the shares. The firm will look for updated guidance on the…
Incyte price target raised to $134 from $117 at Barclays
Barclays raised the firm’s price target on Incyte (INCY) to $134 from $117 and keeps an Overweight rating on the shares. The firm adjusted the price target as part of…
Hemab Therapeutics price target raised to $47 from $39 at Jefferies
Jefferies raised the firm’s price target on Hemab Therapeutics (COAG) to $47 from $39 and keeps a Buy rating on the shares after competitor Incyte’s (INCY) Star unit reported additional…
Incyte price target raised to $112 from $94 at BMO Capital
BMO Capital raised the firm’s price target on Incyte (INCY) to $112 from $94 and keeps a Market Perform rating on the shares as part of a broader research note…
Incyte announces safety, efficacy data from VGA039 study
Incyte (INCY) announced complete safety and efficacy data from all patients enrolled in the Phase 1/2 multidose study of VGA039, a Protein S-targeting, investigational monoclonal antibody for patients...
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Phase 1/2 Multidose Data for VGA039 (Latarcibart) Show Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types.
Incyte to Report Second Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 202...
Incyte price target raised to $99 from $95 at RBC Capital
RBC Capital raised the firm’s price target on Incyte (INCY) to $99 from $95 and keeps a Sector Perform rating on the shares as part of a broader research note…
Incyte completes acquisition of Vega Therapeutics
Incyte (INCY) completed its acquisition of Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics. The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for von Wi...
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio.
Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion
Three outlier inflow signals push biopharmaceutical firm Incyte Corporation (INCY) up 71% in a year.
Incyte announces positive CHMP opinion of Opzelura Cream
Incyte (INCY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the approval of Opzelura cream for the…
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis.
Incyte price target raised to $113 from $103 at UBS
UBS raised the firm’s price target on Incyte (INCY) to $113 from $103 and keeps a Neutral rating on the shares. The firm sees biopharma value stocks such as Incyte…
Incyte price target raised to $105 from $103 at Truist
Truist raised the firm’s price target on Incyte (INCY) to $105 from $103 and keeps a Hold rating on the shares. The firm updated its model ahead of Q2 earnings…
Incyte upgraded to Market Perform from Underperform at BMO Capital
BMO Capital analyst Evan Seigerman upgraded Incyte (INCY) to Market Perform from Underperform with a price target of $94, up from $75. The company has made “meaningful progress” in shifting…
Incyte Japan announces approval of Minjuvi combination for DLBCL
Incyte (INCY) Biosciences Japan G.K. announced that Japan’s Ministry of Health, Labour and Welfare has approved Minjuvi in combination with lenalidomide for the treatment of adults with relapsed or re...
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for Adults with Relapsed or Refractory DLBCL.
Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study
Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced Phase 2 results from Cohort 1 of the Progress study evaluating zilurgisertib, an investigational oral activin receptor-like kinase 2 inhibitor,...
Incyte announces clinical data from two Phase 2 studies of INCA033989
Incyte (INCY) announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin-targeted monoclonal antibody...